Wells Fargo raised the firm’s price target on Eli Lilly to $875 from $825 and keeps an Overweight rating on the shares. The firm continues to like Eli Lilly as Q1 results underscore robust demand of diabesity products. Wells also continues to see beat and raise potential in the near to medium term and the growing pipeline helps the long-term prospects.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- LLY Earnings: Eli Lilly Gains on Strong Q1 Earnings Beat
- Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum
- Notable companies reporting before tomorrow’s open
- Options Volatility and Implied Earnings Moves This Week, April 29 – May 02, 2024
- Eli Lilly And Company (LLY) Q1 Earnings Cheat Sheet
